Aptose Biosciences (TSE:APS) Stock Price Passes Below Fifty Day Moving Average – Here’s Why

Aptose Biosciences Inc. (TSE:APS) (NASDAQ:APTO) crossed below its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of C$2.20 and traded as low as C$2.12. Aptose Biosciences shares last traded at C$2.12, with a volume of 100 shares.

Analyst Upgrades and Downgrades

Separately, Alliance Global Partners lowered shares of Aptose Biosciences from a “strong-buy” rating to a “hold” rating in a research note on Monday, November 24th. One investment analyst has rated the stock with a Hold rating, According to data from MarketBeat.com, Aptose Biosciences presently has an average rating of “Hold”.

Aptose Biosciences Stock Performance

The company has a debt-to-equity ratio of -97.77, a current ratio of 0.53 and a quick ratio of 5.41. The stock has a 50-day moving average price of C$2.20 and a 200-day moving average price of C$2.00. The firm has a market capitalization of C$5.41 million, a PE ratio of 3.07 and a beta of -1.19.

About Aptose Biosciences

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma.